Feng Ye - Concepedia

Author

Feng Ye

Also Known As

Bandera, Elisa V., F.-G. Ye, FENG YE, Feng Ye, Feng, Ye, Nyante, Sarah, Ojengbede, Oladosu, Xiaodong Cheng, Xiaojia Huang, Ye Feng

218

Publications

5.4K

Citations

H-Index

106

Concepts

All Affiliations

Sun Yat-sen University Women's Hospital, School of Medicine, Zhejiang University First Affiliated Hospital of Xiamen University Sun Yat-sen University Cancer Center Sichuan University

About

Feng Ye is an author at Sun Yat-sen University specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	29	2.3K
2	Health Sciences	5	5	448
3	Engineering	3	3	183
4	Natural Sciences	2	2	92
5	Social Sciences	1	1	331

Feng Ye

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
MicroRNA-Mediated Control of Oligodendrocyte Differentiation Xianghui Zhao, Xuelian He, Xiaolei Han, Neuron Developmental BiologyOligodendrocyte DifferentiationMicrorna DetectionSmall RnaGene Expression	2010	484
The oligodendrocyte-specific G protein–coupled receptor GPR17 is a cell-intrinsic timer of myelination Ying Chen, Heng Wu, Wang Shu-zong, Nature Neuroscience Molecular NeuroscienceSignal TransductionMolecular PhysiologyReceptor Gpr17G Protein-coupled Receptor	2009	331
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition Peng Liu, Zehao Wang, Xueqi Ou, Molecular Cancer	2022	208
miR-375 Is Down-Regulated in Squamous Cervical Cancer and Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1 Fenfen Wang, Li Yang, Jiansong Zhou, American Journal Of Pathology Cervical CancerMedicineInhibits Cell MigrationSquamous Cervical CancerCancer Cell Biology	2011	204
Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV‐related target genes for miR‐29 Yang Li, Fenfen Wang, Junfen Xu, The Journal of Pathology	2011	203
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial Shun Lü, Lin Wu, Hong Jian, The Lancet Respiratory Medicine OncologyDisease ProgressionSecond Interim AnalysisMetronomic TherapyClinical Trials	2023	181
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial Jianxing He, Chunxia Su, Wenhua Liang, The Lancet Respiratory Medicine MedicineImmunologyPathologyAdjuvant TreatmentImmune Checkpoint Inhibitor	2021	178
miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression Hailin Tang, Min Deng, Yunyun Tang, Clinical Cancer Research	2013	163
Tomographic subvolume alignment and subvolume classification applied to myosin V and SIV envelope spikes Hanspeter Winkler, Ping Zhu, Jun Liu, Journal of Structural Biology Tomographic Subvolume AlignmentEngineeringMedical ImagingMicroscopyBiomedical Imaging	2008	145
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. Zhenkui Pan, Feng Ye, Xuan Wu, PubMed	2015	139

Page 1